Emergent BioSolutions: FDA to Review AV7909 Anthrax Vaccine Candidate
June 24 2022 - 07:13AM
Dow Jones News
By Colin Kellaher
Emergent BioSolutions Inc. on Friday said the Food and Drug
Administration accepted for review its application seeking approval
of its anthrax vaccine candidate AV7909.
The Gaithersburg, Md., maker of vaccines and therapeutics, which
has spent two decades working with the U.S. government on its
anthrax program, is studying the vaccine for post-exposure
prevention of disease following suspected or confirmed exposure in
people ages 18 through 65 when administered in conjunction with
recommended antibacterial drugs.
Emergent said the FDA set a target action date for a decision in
April 2023.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 24, 2022 06:58 ET (10:58 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Mar 2023 to Mar 2024